hl60 cells

Mitoxantrone (mitozantrone) is an anthracenedione antibiotic with antineoplastic activity. Mitoxantrone intercalates into and crosslinks DNA, thereby disrupting DNA and RNA replication. This agent also binds to topoisomerase II, resulting in DNA strand breaks and inhibition of DNA repair. Mitoxantrone is less cardiotoxic compared to doxorubicin.

Mitoxantrone dihydrochloride (NSC-301739) is the hydrochloride salt of an anthracenedione antibiotic with antineoplastic activity. It is a type II topoisomerase inhibitor.

Phloretin (NSC-407292) is a well-known inhibitor of eukaryotic urea transporters, blocks VacA-mediated urea and ion transport. Phloretin is a dihydrochalcone, a type of natural phenols. It can be found in apple tree leaves and the Manchurian apricot. It promotes potent antioxidative activities in peroxynitrite scavenging and the inhibition of lipid peroxidation. It has been found to inhibit the growth of several cancer cells and induce apoptosis of B16 melanoma and HL60 human leukemia cells.

Ch55 (3,5-Di-tert-butylchalcone) is an effective inducer of the differentiation of HL60 cells (EC50 = 200 nM) and shows high affinity with RAR-α and RAR-β receptors. Ch55 can be used in studies about cancer.

DC1 is an ADC cytotoxin, similar to the small groove-binding DNA alkylating agent CC-1065. DC1 can be used to synthesize antibody-drug conjugates targeted to the treatment of cancer. DC1Sme is a DC1 derivative with IC50 values of Ramos, Namalwa, HL60 s

DC10SMe is a DNA alkylating agent that can be used in the synthesis of antibody-drug conjugates (ADC). The IC50 of DC10SMe for Ramos, Namalwa and HL60 s cancer cells were 15 pM, 12 pM and 12 pM, respectively.

The IC50 of DC44SMe for Ramos, Namalwa and HL60 s cancer cells was 2.0 nM, 2.8 nM and 1.9 nM, respectively. DC44SMe can be used for targeted treatment of cancer. DC44SMe is a phosphate prodrug of DC44 and can be used in the synthesis of antibody-drug co

The IC50s of DC4SMe on Ramos, Namalwa and HL60 s cancer cells were 1.9 nM, 2.9 nM and 1.8 nM, respectively. DC4SMe can be used for targeted therapy of tumors. DC4SMe is a phosphate prodrug of the cytotoxic DNA alkylating agent DC4 and can be used in the

RWJ 50271 is a selective lymphocyte function-associated antigen-1 intercellular adhesion molecule-1(LFA-1 ICAM-1) interaction inhibitor( IC50 of 5.0 μM in HL60 cells).

SGD-1882 (PBD dimer) is a cytotoxic conjugate that is a target for mouse and human hematopoietic stem cells (HSC) and acute myeloid leukemia cells.

HDAC-IN-79 (compound 4) is an orally active dual inhibitor of xanthine oxidase and HDAC, exhibiting potent anti-hyperuricemia and antitumor activities in vivo (Xanthine oxidase: IC50=6.6 nM; HDAC1: IC50=134 nM; HDAC2: IC50=284 nM; HDAC3: IC50=173 nM; HDAC6: IC50=1.32 nM). Among leukemia cells, it is most effective in inhibiting the growth of HL60 cells (IC50=0.706 μM) and induces both apoptosis and autophagy. HDAC-IN-79 also modulates the expression levels of biomarkers associated with intracellular HDAC inhibition.

6-Hydroxycoumarin (6-hydroxychromen-2-one) exhibits cytotoxicity against human HL60, HCT116, COLO205 cells with activity value of 35 uM, 42 uM, 37 respectively. 6-Hydroxycoumarin is a human CA9, CA12 inhibitor.

CAY10503 is a proapoptotic, antiproliferative compound that is able to arrest cell cycle progression in the G0-G1 phase. CAY10503 inhibits the growth of HL60, multidrug resistant HL60R, and K562 cells with IC50 values of 7.0, 23, and 20 μM, respectively. Accumulation of HL60 cells in G0-G1 occurred within eight hours following treatment with 50 μM CAY10503, whereas 10 μM CAY10503 required 96 hours for cell cycle arrest to appear. CAY10503 also induces differentiation of HL60 cells into the following positive cells: CD14 (monocytic marker) as well as CD11b and CD11c (granulocytic markers). Approximately 60% of HL60 cells exposed to 10 μM CAY10503 expressed these markers within 72 hours.

Gracillin can induce cell cycle arrest, oxidative stress, and apoptosis in HL60 cells, and has the potential to be developed as an antitumor agent. Gracillin can be selected as lead compounds for the development of new drugs against I. multifiliis.

S-(N-PhenethylthiocarbaMoyl)-L-cysteine (PEITC-Cys) is an anticarcinogenic agent that exhibits antileukemic activity by inhibiting DNA synthesis in HL60 cells [1] and acts as an inhibitor of P450 [2].

PI3K-IN-29, a potent inhibitor of PI3K, exhibits substantial inhibition capabilities against U87MG, HeLa, and HL60 cells, with IC50 values of 0.264, 2.04, and 1.14 µM, respectively. It effectively blocks the PI3K Akt signaling pathway by preventing the PI3K-catalyzed phosphorylation of Akt [1].

O-Allylvanillin, an O-allylchalcone derivative, exhibits anti-cancer properties by inhibiting the growth of THP-1, HL60, Hep-G2, and MCF-7 cells with IC50 values of 74.76 μM, 63.52 μM, 90.99 μM, and 90.11 μM, respectively [1].

BCL6-IN-10 (Compound WK499) is an inhibitor of BCL6 that disrupts its interaction with the SMRT protein, promoting apoptosis, cell cycle arrest, and DNA damage. It effectively hampers the proliferation of various AML cell lines, with IC50 values of 0.91, 1.63, 1.026, 7.42, 0.87, and 0.85 μM for OCI-AML3, THP1, MOLM13, HL60, KG1, and NB4 cells, respectively [1].

Compound 2v (Anti-inflammatory agent 45) demonstrates anticancer properties with direct inhibitory impacts on the proliferation of various blood malignancies, such as leukemia, lymphoma, and myeloma cell lines. It induces apoptosis and suppresses nitric oxide production in HL60 leukemia cells (IC50 = 14.7 μM) [1].

HDAC CD13-IN-1 (Compound 12) is an inhibitor of both HDAC and CD13, with IC50 values of 0.34 μM for hCD13, 0.53 μM for porcine CD13, and 0.03, 0.06, and 0.02 μM for HDAC1, HDAC2, and HDAC3, respectively. This compound effectively suppresses proliferation and induces apoptosis in MV4-11, K562, Jeko-1, and HL60 cancer cells, with IC50 ranges of 0.25-2.04 μM, and demonstrates capabilities in hindering metastasis and invasion [1].

Theasaponin E2, isolated from Camellia sinensis [1], exhibits cytotoxicity against K562 and HL60 cells with an IC50 of 14.7 μg mL.

c-Myc Inhibitor 14 (Compound 13A), an inhibitor of the c-Myc protein, exhibits an IC50 value of less than 100 nM in HL60 cells. This compound demonstrates antitumor activity [1].

Ap4A (1, 10 µM; 24 h) induces apoptosis in HL60 cells.

28-Deoxonimbolide exhibits potent cytotoxic activity against HL60 leukemia cells.